Browse By

YHB Investment Advisors Inc. Has $233,000 Stake in Boston Scientific Corporation (BSX)

Boston Scientific Corporation logoYHB Investment Advisors Inc. decreased its position in Boston Scientific Corporation (NYSE:BSX) by 7.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 8,400 shares of the medical equipment provider’s stock after selling 720 shares during the period. YHB Investment Advisors Inc.’s holdings in Boston Scientific Corporation were worth $233,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Toronto Dominion Bank raised its position in Boston Scientific Corporation by 56.7% in the first quarter. Toronto Dominion Bank now owns 367,924 shares of the medical equipment provider’s stock worth $9,150,000 after buying an additional 133,121 shares during the last quarter. Koch Industries Inc. acquired a new position in Boston Scientific Corporation during the first quarter worth $307,000. Bellevue Group AG raised its position in Boston Scientific Corporation by 4.0% in the first quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock worth $14,226,000 after buying an additional 22,000 shares during the last quarter. Principal Financial Group Inc. raised its position in Boston Scientific Corporation by 1.7% in the first quarter. Principal Financial Group Inc. now owns 1,983,944 shares of the medical equipment provider’s stock worth $49,340,000 after buying an additional 33,763 shares during the last quarter. Finally, Morgan Stanley raised its position in Boston Scientific Corporation by 63.8% in the first quarter. Morgan Stanley now owns 3,744,380 shares of the medical equipment provider’s stock worth $93,124,000 after buying an additional 1,458,906 shares during the last quarter. Institutional investors own 91.96% of the company’s stock.

Get Boston Scientific Corporation alerts:

Shares of Boston Scientific Corporation (NYSE BSX) opened at 26.74 on Friday. The stock’s 50 day moving average price is $27.64 and its 200 day moving average price is $25.93. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $28.51. The firm has a market capitalization of $36.65 billion, a price-to-earnings ratio of 47.84 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm posted $0.27 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://transcriptdaily.com/2017/08/04/yhb-investment-advisors-inc-has-233000-stake-in-boston-scientific-corporation-bsx.html.

BSX has been the topic of a number of recent analyst reports. Jefferies Group LLC boosted their target price on Boston Scientific Corporation from $26.00 to $28.00 and gave the stock a “hold” rating in a report on Friday, April 7th. Guggenheim reissued a “buy” rating on shares of Boston Scientific Corporation in a report on Wednesday, April 12th. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, April 24th. TheStreet raised Boston Scientific Corporation from a “c+” rating to a “b” rating in a report on Tuesday, April 25th. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 target price (up from $29.00) on shares of Boston Scientific Corporation in a report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Boston Scientific Corporation has an average rating of “Buy” and a consensus price target of $30.06.

In other Boston Scientific Corporation news, SVP John Bradley Sorenson sold 2,100 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $27.15, for a total transaction of $57,015.00. Following the sale, the senior vice president now directly owns 18,880 shares in the company, valued at approximately $512,592. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Timothy A. Pratt sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $27.13, for a total transaction of $271,300.00. Following the sale, the executive vice president now owns 215,846 shares in the company, valued at $5,855,901.98. The disclosure for this sale can be found here. In the last three months, insiders sold 216,156 shares of company stock valued at $5,899,982. Corporate insiders own 0.74% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *